Corporate News

Director/PDMR Shareholding

05 June 2020

Concepta plc (AIM:CPT),  the UK healthcare company and developer of a proprietary product targeted at the mobile health market and with a primary focus on women's fertility, today   announces that  share options over 13,000,000   ordinary shares of the Company (representing approximately 2.65% of the issued ordinary share capital) under the Company's EMI Share Option Scheme at an exercise price of 0.8p per share, being the price of the shares allotted at the General Meeting on 24 April 2020, and have been awarded as follows:

10,000,000 to Penny McCormick

The Options shall time vest as follows:

The options will vest in equal tranches over 3 years from the date of commencement of Mrs McCormick's employment (of 14 November 2019):


3,333,333 on 14 November 2020

3,333,333 on 14 November 2021

3,333,334 on 14 November 2022


2,500,000 to Maddy Kennedy

The Options shall time vest as follows:

The options will vest in full over 1 year from the date of commencement of Mrs Kennedy's employment (of 24 October 2019):


2,500,000 on 24 October 2020


500,000 to Karen Whiting

The Options shall time vest as follows:

The options will vest in equal tranches over 3 years from the date of commencement of Mrs Whiting's employment (of 2 March 2020):


166,667 on 2 March 2021

166,667 on 2 March 2022

166,666 on 2 March 2023



Concepta plc

Penny McCormick , Chief Executive Officer

via Walbrook PR

Maddy Kennedy, Chief Financial Officer


SPARK Advisory Partners Limited (NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin


Novum Securities (Broker)

Tel: +44 (0)20 7399 9400

Colin Rowbury


Walbrook PR Ltd (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus

Mob: +44(0)7980 541 893


About Concepta PLC ( )

Concepta PLC is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus®, targeted at the personalized mobile health market with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant and to provide insight to unexplained infertility.

myLotus® is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus®   is to empower women to better understand their hormone levels and menstrual cycle and help women conceive naturally by identifying their window of fertility and optimal time for conception.

The Company has received CE-mark certification for myLotus®   and has launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2020.

myLotus® is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.